Agustin Garcia, MD
Medical Oncology · Independence, LANPI 1942258116
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,675 of the $13,275 with a category attached, or 65.3%. 35 manufacturers reported payments, led by Daiichi Sankyo Inc. at 46.2% of the total. Reporting peaked in 2019 at $10,765 and has fallen 93.1% since, to $741 in 2025.
Across 185 payments — averaging $71.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$6K
- Tesaro, Inc.$2K
- Eisai Inc.$2K
- Novartis$647
- Pfizer$279
- Gilead$264
- plus $2K from 29 others
Across 38 payments — averaging $3339.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$82K
- Eisai Inc.$29K
- Seagen Inc.$12K
- Iovance Biotherapeutics, Inc.$4K
- Sanofi US Services Inc.$671
What the payments were for
- Consulting fees$8,67565%
- Travel & lodging$1,2129%
- Food & beverage$3,31225%
- Education$761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 16 | $6,128 |
| Tesaro, Inc. | 4 | $2,155 |
| Eisai Inc. | 3 | $2,065 |
| Novartis | 41 | $647 |
| Pfizer | 16 | $279 |
| Gilead | 16 | $264 |
| Merck | 12 | $192 |
| E.r. Squibb & Sons, L.L.C. | 10 | $183 |
| Clovis Oncology, Inc. | 5 | $180 |
| Stemline Therapeutics Inc. | 8 | $152 |
| Recordati_rare_diseases_inc. | 5 | $124 |
| AbbVie | 5 | $104 |
| Sanofi | 4 | $87 |
| AstraZeneca | 5 | $85 |
| Array Biopharma Inc | 4 | $80 |
| Bristol Myers Squibb | 4 | $75 |
| Exelixis Inc. | 3 | $59 |
| Genentech USA, Inc. | 3 | $51 |
| Amgen | 2 | $38 |
| Bayer | 3 | $36 |
| Beigene USA, Inc. | 2 | $34 |
| Tersera Therapeutics LLC | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $25 |
| Roche Diagnostics Corporation | 1 | $24 |
| Astellas Pharma US Inc | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Mylan Institutional Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| GSK | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| CTI Biopharma Corp. | 1 | $14 |
| Organon | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 20 | $332,701 |
| IbrancePalbociclib | 17 | $272,754 |
| RevlimidLenalidomide | 15 | $245,125 |
| KisqaliRibociclib Succinate | 23 | $224,473 |
| EliquisApixaban | 29 | $17,112 |
| XareltoRivaroxaban | 11 | $10,675 |
| VeozahFezolinetant | 12 | $6,525 |
| Exemestane | 49 | $5,302 |
| Anastrozole | 247 | $2,821 |
| Tamoxifen Citrate | 93 | $1,506 |
| Ibandronate Sodium | 72 | $914 |
| Morphine Sulfate | 12 | $601 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $488 |
| Letrozole | 28 | $478 |
| Alendronate Sodium | 81 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $279 | $289,86646 claims |
| Bristol Myers SquibbRevlimid | $75 | $245,12515 claims |
| NovartisKisqali | $647 | $224,47323 claims |
| Johnson & JohnsonXarelto | $19 | $10,67511 claims |
| Astellas Pharma US IncVeozah | $20 | $6,52512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Independence
- Daniel JohnsonNew Orleans$329K
- Laura FinnNew Orleans$171K
- Michael CastineBaton Rouge$165K
- Gerald MiletelloBaton Rouge$26K
- Pavani EllipeddiBaton Rouge$11K
- Cody MillimanBaton Rouge$7K
- Elizabeth LejeuneLafayette$6K
- Joseph BrierreLafayette$5K
- Srikanth TammaNew Orleans$4K
- Constance BluntBaton Rouge$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.